Invivyd, Inc. (IVVD) Earnings Call Transcripts

Invivyd, Inc.'s Latest Earnings Call - April 9, 2026

In the first quarter of fiscal year 2026, Invivyd, Inc. (IVVD:US) reported significant advancements in its REVOLUTION program, particularly with the VYD2311 monoclonal antibody for COVID-19 and the new measles candidate VMS063. The company emphasized its commitment to addressing ongoing COVID-19 challenges and the rising measles outbreaks in the U.S. Revenue and earnings details were not disclosed during the call, but management expressed optimism about future clinical developments and regulatory engagements. Notably, the company has upsized its DECLARATION study to ensure robust statistical power, indicating confidence in its clinical strategy moving forward.

Reported metrics

Guidance from management

Management is optimistic about the upcoming clinical profiles of VYD2311 and VMS063, with plans to prepare for a BLA filing for VYD2311 later this year. They are also looking to initiate the LIBERTY study shortly, assessing the safety and immunology of monoclonal antibodies versus mRNA vaccines.

What management said

Thanks so much, Michael and Robbie. We're really excited about the future of Invivyd in COVID-19 and beyond. As you can tell from our early discovery pipeline here on Slide 18, there are great many viruses, including viruses that are vaccine preventable that may be very attractive targets for our technology as we work to lower the burden of disease in America and provide a complement to active vaccination. There have...

What analysts pressed on

Analysts expressed concerns regarding the timing of the next COVID wave and its impact on study powering. There were also questions about the regulatory strategy for VMS063 and how it will compete with existing vaccines in the market.

Main topics on the call

• VYD2311 Clinical Progress — Invivyd is making strides with its VYD2311 monoclonal antibody, designed to prevent COVID-19. Management stated, "we are pleased with today's update to begin to turn our attention from event accumulation to now preparing...
• Measles Antibody Development — The company introduced VMS063 as a potential first-in-class measles monoclonal antibody, with Dr. Mina stating, "we believe measles may be highly responsive to monoclonal antibody prophylaxis and therapy." This highlight...
• Upsizing of DECLARATION Study — Management announced a prespecified interim sample size re-estimation, stating, "we set this algorithm to be conservative in effect to dictate upsizing..." This decision reflects a proactive approach to ensure the study'...
• Regulatory Engagements — Invivyd has achieved alignment with the U.S. FDA on a pediatric study plan for VYD2311, with management noting, "they have responded by recommending a parallel group design, including infants and babies aged 0 to 2." Thi...

Read the full Invivyd, Inc. transcript (April 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 Invivyd, Inc. earnings call transcripts on record, spanning November 10, 2022 to May 14, 2026. Based on this history, Invivyd, Inc. reports quarterly. The most recent call on file is dated May 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IVVD

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

21

First call

November 10, 2022

Most recent

May 14, 2026

Reporting cadence

quarterly